2024 World Conference on Lung Cancer (WCLC) - Posters-P1.06A.03 Use of Biosimulation to Predict Concomitant Chemotherapy Benefit in NSCLC Patients with EGFR Mutations Being Treated with Osimertinib

P1.06A.03 Use of Biosimulation to Predict Concomitant Chemotherapy Benefit in NSCLC Patients with EGFR Mutations Being Treated with Osimertinib

Back to course

Pdf Summary

The study explores the use of biosimulation to predict the benefits of adding chemotherapy to targeted therapy in non-small cell lung cancer (NSCLC) patients with EGFR mutations treated with osimertinib. Targeted therapy is typically effective for such patients; however, the potential benefit from additional chemotherapy varies among individuals.<br /><br />Researchers employed a computational biology model (CBM) using retrospective data from 116 patients, sourced from the Flatiron Health-Foundation Medicine NSCLC clinico-genomic database. The efficacy of treatments was assessed by generating scores based on computational simulations of cell growth responses to therapy, analyzing both osimertinib alone and in combination with chemotherapy agents carboplatin and pemetrexed.<br /><br />The key findings indicate that osimertinib efficacy scores were significantly associated with clinical response and progression-free survival (PFS). All patients showed increased predicted efficacy scores with the addition of chemotherapy, though the degree of benefit varied. The study projected that including chemotherapy could increase the objective response rate (ORR) from 75% to 91%, aligning with published data.<br /><br />The analysis also identified genetic markers influencing the level of benefit derived from chemotherapy; patients with deficiencies in DNA repair genes such as ATM and SMARCA4 were likely to benefit more, while those with TP53 mutations and EGFR copy number gains were predicted to benefit less.<br /><br />The study concludes that computational biosimulation could be a valuable tool in determining which patients would benefit from concomitant chemotherapy, prompting further research to validate these findings.

Asset Subtitle

Charu Aggarwal

Meta Tag

Speaker Charu Aggarwal

Topic Pathology & Biomarkers

Keywords

biosimulation

chemotherapy

targeted therapy

non-small cell lung cancer

NSCLC

EGFR mutations

osimertinib

computational biology model

clinical response

genetic markers